<?xml version="1.0" ?><ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput xmlns:ns2="local" id="1f1ee76a-399a-4475-893f-26d20ee02791" dataset="sourcesCorporatePublication" time="40"><serviceExecutionTime>52</serviceExecutionTime><lastDatasetUpdate>2019-02-16T00:12:36Z</lastDatasetUpdate><PagedResults total="1365" firstRow="11" lastRow="150"><Result pos="11"><Field name="sourceId" type="string">175194</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Remune, AI-208, IR-501, vaccine (colon cancer), IRC/SKCC, GeneDrug, IR-502</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-03-15T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">The Immune Response Corporation</Field></Result><Result pos="12"><Field name="sourceId" type="string">195137</Field><Field name="corporatePublicationTitle" type="string">Use of CEA-Scan in planning for resection of recurrent and/or metastatic colorectal cancer</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-07-03T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Immunomedics Inc</Field></Result><Result pos="13"><Field name="sourceId" type="string">182244</Field><Field name="corporatePublicationTitle" type="string">Prospective grant of license: Tumor infiltrating lymphocytes as a treatment modality for human cancer</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-07-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institutes of Health</Field></Result><Result pos="14"><Field name="sourceId" type="string">183391</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Theragyn</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-08-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Imperial Cancer Research Technology Ltd</Field></Result><Result pos="15"><Field name="sourceId" type="string">183672</Field><Field name="corporatePublicationTitle" type="string">Genes and Breast Cancer. research breakthroughs open up promising new avenues for diagnosis and treatment</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-08-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Canji Inc</Field></Result><Result pos="16"><Field name="sourceId" type="string">189939</Field><Field name="corporatePublicationTitle" type="string">Kinase Inhibitor Program Cancer and Anti-Fungal Therapeutics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-10-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Mitotix Inc</Field></Result><Result pos="17"><Field name="sourceId" type="string">189938</Field><Field name="corporatePublicationTitle" type="string">Phosphatase Inhibitors: Cancer/Anti-fungal/Cardiovascular Therapeutics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-10-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Mitotix Inc</Field></Result><Result pos="18"><Field name="sourceId" type="string">189935</Field><Field name="corporatePublicationTitle" type="string">Intracellular Proteolysis Program: Cancer and Anti-Inflammatory Therapeutics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-10-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Mitotix Inc</Field></Result><Result pos="19"><Field name="sourceId" type="string">193417</Field><Field name="corporatePublicationTitle" type="string">BIOMIRA, Dedicated to the diagnosis and treatment of cancer</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-11-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biomira Inc</Field></Result><Result pos="20"><Field name="sourceId" type="string">228406</Field><Field name="corporatePublicationTitle" type="string">Annual Report 1995 - Ludwig Institute for Cancer Research (Australia)</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">1995-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ludwig Institute for Cancer Research (Australia)</Field></Result><Result pos="21"><Field name="sourceId" type="string">200065</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ImmuRAID-LL1, CEA-Scan, ImmuRAID-AFP-Tc-99m, Immunomedics and ImmuRAID-HCG-Tc-99m, Immunomedics, lymphoScan, sulesomab, AFP-Cide, CEA-Cide, ImmuRAID-HCG(I-131), Immunomedics, ImmuRAIT-LL2, ImmuRAIT-CEA-rhenium-188, Immunomedics, immutox (humanized form), Immunomedics, PCP-Scan, DOX-CEA, rhenium-188-LL2, Immunomedics, vaccine (cancer) (1), Immunomedics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-02-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Immunomedics Inc</Field></Result><Result pos="22"><Field name="sourceId" type="string">422395</Field><Field name="corporatePublicationTitle" type="string">Breast cancer Clinical trials of a new drug Search which led to the development of EM-800 started at the Molecular Laboratory of Endocrinology in 1992</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-02-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Universite Laval</Field></Result><Result pos="23"><Field name="sourceId" type="string">206111</Field><Field name="corporatePublicationTitle" type="string">Cell Pathways Inc Chemoprevention - a new approach to cancer</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-04-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cell Pathways Inc</Field></Result><Result pos="24"><Field name="sourceId" type="string">217501</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ribozymes (cancer), Ribozyme, LY-466700, ribozymes (VEGF), Ribozyme, ProtoGene, ribozymes (osteoarthritis), Ribozyme</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-08-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ribozyme Pharmaceuticals Inc</Field></Result><Result pos="25"><Field name="sourceId" type="string">220577</Field><Field name="corporatePublicationTitle" type="string">Re: ERIC-1, ICRT</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-10-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Imperial Cancer Research Technology Ltd</Field></Result><Result pos="26"><Field name="sourceId" type="string">220635</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: vaccine (cancer), Sandoz/Wistar, vaccine (GI tumor), Wistar</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-10-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="27"><Field name="sourceId" type="string">221096</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: gene therapy (cancer), MediGene, CHF therapy, MediGene, antibacterials, MediGene</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-10-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MediGene GmbH</Field></Result><Result pos="28"><Field name="sourceId" type="string">222486</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: interleukin-2 vaccine</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-10-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Institute of Cancer Research, UK</Field></Result><Result pos="29"><Field name="sourceId" type="string">221892</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: microsponge (tretinoin), colon specific DDS (budesonide), polyorthoester DDS (cancer), Hydrosponge (topical DDS), bioerodible DDS (vaccine), microsponge (gastrointestinal disease), microsponge (periodontal)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-10-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Advanced Polymer Systems</Field></Result><Result pos="30"><Field name="sourceId" type="string">224278</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: CFGT, GenVec, radition therapy, GenVec, vector technology, Theragen, gene therapy (colon cancer), GenVec, ADGVVEGF121.10, HSV type 1 mutant, BTG</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-11-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">GenVec Inc</Field></Result><Result pos="31"><Field name="sourceId" type="string">228115</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Abiraterone</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-12-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign (UK)</Field></Result><Result pos="32"><Field name="sourceId" type="string">228668</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: DOX-LL2, Immunomedics, DOX-CEA, CEA-Scan, immunoconjugates (cancer), Immunomedics, ImmunRAIT-HCGI(I-131), Immunomedics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-12-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Immunomedics Inc</Field></Result><Result pos="33"><Field name="sourceId" type="string">229103</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: antagonist D, ICRF, gene therapy (interleukin-2), ICRF and gene therapy (breast cancer), ICRF</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-12-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Imperial Cancer Research Technology Ltd</Field></Result><Result pos="34"><Field name="sourceId" type="string">255412</Field><Field name="corporatePublicationTitle" type="string">Annual Report 1996 - Memorial Sloan Kettering Cancer Center Institute</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Memorial Sloan Kettering Cancer Center Institute</Field></Result><Result pos="35"><Field name="sourceId" type="string">253711</Field><Field name="corporatePublicationTitle" type="string">Annual Report 1996 - Cancer Research Campaign (UK)</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">1996-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign (UK)</Field></Result><Result pos="36"><Field name="sourceId" type="string">236828</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: lung cancer therapy, Cadus, asthma therapy, Cadus</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-03-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cadus Pharmaceutical Corp</Field></Result><Result pos="37"><Field name="sourceId" type="string">238147</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: gene therapy (cancer), Oxford BioMedica, gene therapy (parkinson disease), Oxford BioMedica, gene therapy (HIV), Oxford BioMedica, gene delivery technology, Oxford BioMedica, retroviral vectors, Oxford BioMedica</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-03-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Oxford Biomedica Ltd</Field></Result><Result pos="38"><Field name="sourceId" type="string">241356</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: EPICOAT cancer vaccine, Axis</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-03-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Axis Genetics</Field></Result><Result pos="39"><Field name="sourceId" type="string">251348</Field><Field name="corporatePublicationTitle" type="string">Novel Human Cancer Antigen of Tyrosinase-Related Proteins 1 and 2 and Genes Encoding Same</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-06-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institutes of Health</Field></Result><Result pos="40"><Field name="sourceId" type="string">261258</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: abciximab, edrecolomab, infliximab, Factor VIIa inhibitor, Corvas, GeneVax vaccine (cancer), Centocor</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-08-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Centocor Inc</Field></Result><Result pos="41"><Field name="sourceId" type="string">352407</Field><Field name="corporatePublicationTitle" type="string">Breakdown of NCI-identified ovarian cancer clinical trial</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-09-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="42"><Field name="sourceId" type="string">265939</Field><Field name="corporatePublicationTitle" type="string">Development of a vaccine for breast cancer</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-10-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Medical Innovation Limited</Field></Result><Result pos="43"><Field name="sourceId" type="string">265669</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: gene therapy (cancer), IDUN, ICE inhibitors, IDUN, bcl-2 antagonists, IDUN</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-10-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">IDUN Pharmaceuticals Inc</Field></Result><Result pos="44"><Field name="sourceId" type="string">274956</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Calydon's prostate cancer therapy</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1997-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Calydon Inc</Field></Result><Result pos="45"><Field name="sourceId" type="string">280191</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Suicide gene therapy (cancer), NIH</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-03-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institutes of Health</Field></Result><Result pos="46"><Field name="sourceId" type="string">286036</Field><Field name="corporatePublicationTitle" type="string">Myriad Genetics and Rockefeller University enter into cancer gene agreement</Field><Field name="corporatePublicationType" type="string">Securities and Exchange Commission Form DEF-14</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-04-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Myriad Genetics Inc</Field></Result><Result pos="47"><Field name="sourceId" type="string">292920</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ASP-05, gene therapy (schizophrenia), gene therapy (pain), gene therapy (cancer), BAY-44-3428, gene discovery (asthma), human growth hormone mimics, Factor Xa inhibitors</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-07-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Axys Pharmaceuticals Inc</Field></Result><Result pos="48"><Field name="sourceId" type="string">504308</Field><Field name="corporatePublicationTitle" type="string">GTx, Inc. and the University of Tennessee Research Corporation have entered into a license agreement in which GTx, Inc. has received an exclusive license for the worldwide rights to patent applications covering methods for preventing prostate carcinogenesis and suppressing or inhibiting prostate cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-07-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">GTx Inc</Field></Result><Result pos="49"><Field name="sourceId" type="string">293625</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Phytera and Chiron collaborating to develop cancer therapeutics</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-08-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Phytera Inc</Field></Result><Result pos="50"><Field name="sourceId" type="string">311630</Field><Field name="corporatePublicationTitle" type="string">Company Brochure - Intracel Corp, management of patients with cancer and infectious diseases</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-08-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Intracel Corp</Field></Result><Result pos="51"><Field name="sourceId" type="string">298816</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: cancer vaccine, Memorial sloane-Kettering/PowderJect</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-09-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">PowderJect Pharmaceuticals plc</Field></Result><Result pos="52"><Field name="sourceId" type="string">301611</Field><Field name="corporatePublicationTitle" type="string">Intratumoral focused chemotherapy. A new weapon against cancer</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-10-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Matrix Pharmaceutical Inc</Field></Result><Result pos="53"><Field name="sourceId" type="string">305625</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: NSC-645306</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-11-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="54"><Field name="sourceId" type="string">363966</Field><Field name="corporatePublicationTitle" type="string">Annual Report 1998 - Cancer Prevention Research Program, NCI</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="55"><Field name="sourceId" type="string">312016</Field><Field name="corporatePublicationTitle" type="string">Leukemia insights newsletter</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">1998-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MD Anderson Cancer Center</Field></Result><Result pos="56"><Field name="sourceId" type="string">310892</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: OncoVax-cl, vaccine (colon cancer), Intracel</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-01-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Jenner Biotherapies Inc</Field></Result><Result pos="57"><Field name="sourceId" type="string">313307</Field><Field name="corporatePublicationTitle" type="string">Vaccine created from gene therapy found to be effective in treating ovarian cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-02-03T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Tulane University</Field></Result><Result pos="58"><Field name="sourceId" type="string">315315</Field><Field name="corporatePublicationTitle" type="string">Dan Mercola's Gene Therapy Program Inhibition of prostate, glioblastoma, lung and breast tumor cell growth</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-02-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Sidney Kimmel Cancer Center</Field></Result><Result pos="59"><Field name="sourceId" type="string">316709</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: PFA prodrugs, Allovectin-7, Leuvectin, gene therapy (cancer), Vical/Corixa, gene therapy (hemophilia), Baxter/Vical</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-03-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Vical Inc</Field></Result><Result pos="60"><Field name="sourceId" type="string">317978</Field><Field name="corporatePublicationTitle" type="string">NCI Cancer Trials: Anti-angiogenesis inihibitors in clinical trials</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-03-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="61"><Field name="sourceId" type="string">318291</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Norwalk EPVaccine, Axis/Genetics, cholera EPVaccine, Axis/Genetics, E coli EPVaccine, Axis/Genetics, EPICOAT cancer vaccine, Axis, vaccine (S aureus), Axis</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-03-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Axis Genetics plc</Field></Result><Result pos="62"><Field name="sourceId" type="string">318316</Field><Field name="corporatePublicationTitle" type="string">Cancer trials: antiangiogenesis inhibitors in clinical trials</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-03-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="63"><Field name="sourceId" type="string">322142</Field><Field name="corporatePublicationTitle" type="string">Combination therapy. F-ddA in combination with stavudine and nelfinavir: A phase I Study.</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-04-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="64"><Field name="sourceId" type="string">323575</Field><Field name="corporatePublicationTitle" type="string">Projects: Infectious diseases and cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-05-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Pierre Fabre SA</Field></Result><Result pos="65"><Field name="sourceId" type="string">324407</Field><Field name="corporatePublicationTitle" type="string">Collaborative research: Anti-idiotypic antibodies for the immunotherapy of colo-rectal cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign Technology Ltd</Field></Result><Result pos="66"><Field name="sourceId" type="string">324989</Field><Field name="corporatePublicationTitle" type="string">General Info</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-05-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">John Wayne Cancer Institute</Field></Result><Result pos="67"><Field name="sourceId" type="string">326151</Field><Field name="corporatePublicationTitle" type="string">PHOTODYNAMIC THERAPY (PDT) IN THE TREATMENT OF CANCER AT ROSWELL PARK CANCER INSTITUTE (RPCI)</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-05-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Roswell Park Cancer Institute</Field></Result><Result pos="68"><Field name="sourceId" type="string">328100</Field><Field name="corporatePublicationTitle" type="string">Cancer drugs</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-06-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">BTG plc</Field></Result><Result pos="69"><Field name="sourceId" type="string">329889</Field><Field name="corporatePublicationTitle" type="string">Developmental Therapeutics Program - Status of Compounds</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-06-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="70"><Field name="sourceId" type="string">333851</Field><Field name="corporatePublicationTitle" type="string">Angiogenesis inhibitors in clinical trials</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-07-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="71"><Field name="sourceId" type="string">363965</Field><Field name="corporatePublicationTitle" type="string">Prevention Post: an introduction to the research groups: Lung and Upper Aerodigestive Cancer RG</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-12-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="72"><Field name="sourceId" type="string">351213</Field><Field name="corporatePublicationTitle" type="string">Research and Development: GL-331 for cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-12-21T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Genelabs Technologies Inc</Field></Result><Result pos="73"><Field name="sourceId" type="string">411096</Field><Field name="corporatePublicationTitle" type="string">Annual Research Report 1999 - Institute for Cancer Research</Field><Field name="corporatePublicationType" type="string">Annual Report</Field><Field name="corporatePublicationDatePublication" type="datetime">1999-12-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ludwig Institute for Cancer Research</Field></Result><Result pos="74"><Field name="sourceId" type="string">459086</Field><Field name="corporatePublicationTitle" type="string">Cancer Therapy: Binary Modes</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-01-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Weizmann Institute of Science</Field></Result><Result pos="75"><Field name="sourceId" type="string">354129</Field><Field name="corporatePublicationTitle" type="string">Angiogenesis inhibitors in clinical trials/Phase I study of PTK787/ZK 222584 in patients with HIV-associated Kaposi's Sarcome</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-02-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="76"><Field name="sourceId" type="string">357645</Field><Field name="corporatePublicationTitle" type="string">Univera develops a novel aloe polysaccharide to reduce the risk of skin cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-02-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Univera Pharmaceuticals Inc</Field></Result><Result pos="77"><Field name="sourceId" type="string">357795</Field><Field name="corporatePublicationTitle" type="string">Biomodulation to enhance cancer chemotherapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-03-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biokeys Pharmaceuticals Inc</Field></Result><Result pos="78"><Field name="sourceId" type="string">357769</Field><Field name="corporatePublicationTitle" type="string">Organoselones in Cancer Chemotherapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-03-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biokeys Pharmaceuticals Inc</Field></Result><Result pos="79"><Field name="sourceId" type="string">361663</Field><Field name="corporatePublicationTitle" type="string">Cytoclonal Pharmaceuticals: technology/human gene program/lung cancer gene</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-04-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cytoclonal Pharmaceutics Inc</Field></Result><Result pos="80"><Field name="sourceId" type="string">361842</Field><Field name="corporatePublicationTitle" type="string">IDN-5109, a new taxane for the fight against cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-04-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Idena SpA</Field></Result><Result pos="81"><Field name="sourceId" type="string">363537</Field><Field name="corporatePublicationTitle" type="string">NCI Cancer Trials: Anti-angiogenesis inihibitors in clinical trials</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-04-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="82"><Field name="sourceId" type="string">364908</Field><Field name="corporatePublicationTitle" type="string">Intracel BCI-immuneactivator for the treatment of bladder cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-05-03T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Intracel Corp</Field></Result><Result pos="83"><Field name="sourceId" type="string">490848</Field><Field name="corporatePublicationTitle" type="string">Fenretinide to Prevent Cancer Recurrence in Treating Patients With Bladder Cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-07-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institutes of Health</Field></Result><Result pos="84"><Field name="sourceId" type="string">379239</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: diabetes therapeutics, OP-1, Chondrogel, Neo-bladder, Vascugel, skin cancer therapy (basal cell carcinoma), hedgehog proteins</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-08-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Curis Inc</Field></Result><Result pos="85"><Field name="sourceId" type="string">387697</Field><Field name="corporatePublicationTitle" type="string">AltaRex - Changing the course of cancer therapy</Field><Field name="corporatePublicationType" type="string">Company Brochure</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-09-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">AltaRex Corp</Field></Result><Result pos="86"><Field name="sourceId" type="string">384946</Field><Field name="corporatePublicationTitle" type="string">Independent comment on L-778123</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-10-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Institute New Jersey</Field></Result><Result pos="87"><Field name="sourceId" type="string">422291</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: ovarian cancer therapy, Atairgin</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-11-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Atairgin Technologies Inc</Field></Result><Result pos="88"><Field name="sourceId" type="string">430811</Field><Field name="corporatePublicationTitle" type="string">Gene-based cancer vaccine</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-11-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Oxford BioMedica</Field></Result><Result pos="89"><Field name="sourceId" type="string">391843</Field><Field name="corporatePublicationTitle" type="string">Independent comment on LG-370020, BMS-207977 and CP-347589</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-11-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">H Lee Moffitt Cancer Center &amp; Research Institute</Field></Result><Result pos="90"><Field name="sourceId" type="string">422323</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: macrocyclic taxoids, SUNY/Roswell Park Cancer Institute</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-12-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">State University of New York Stony Brook</Field></Result><Result pos="91"><Field name="sourceId" type="string">422245</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: drug discovery (cancer), VIMRx/Columbia University</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-12-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Columbia University</Field></Result><Result pos="92"><Field name="sourceId" type="string">394017</Field><Field name="corporatePublicationTitle" type="string">Seattle Genetics mAbs for cancer: lead agents</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2000-12-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Seattle Genetics Inc</Field></Result><Result pos="93"><Field name="sourceId" type="string">396524</Field><Field name="corporatePublicationTitle" type="string">The Cancer Institute of New Jersey. Active clinical trials as of 12/14/2000</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-01-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Medicine and Dentistry of New Jersey</Field></Result><Result pos="94"><Field name="sourceId" type="string">405992</Field><Field name="corporatePublicationTitle" type="string">Antibodies to urothelial apical surface antigens for the detection, classification and treatment of bladder cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-04-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="95"><Field name="sourceId" type="string">408572</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline - SU-6668</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign</Field></Result><Result pos="96"><Field name="sourceId" type="string">409225</Field><Field name="corporatePublicationTitle" type="string">Pipeline opportunities: non-cancer programs: Flk-1/KDR in opthalmology</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-05-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SUGEN Inc</Field></Result><Result pos="97"><Field name="sourceId" type="string">432574</Field><Field name="corporatePublicationTitle" type="string">Oncology/immune disorders: cancer vaccine</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-05-29T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">QLT Inc</Field></Result><Result pos="98"><Field name="sourceId" type="string">411264</Field><Field name="corporatePublicationTitle" type="string">Rebeccamycin analog</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-05-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="99"><Field name="sourceId" type="string">411738</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline - mitoflaxone</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-06-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign Technology Ltd</Field></Result><Result pos="100"><Field name="sourceId" type="string">413538</Field><Field name="corporatePublicationTitle" type="string">SU-6668 - phase I trial at the Royal Marsden Hospital, UK</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-06-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign</Field></Result><Result pos="101"><Field name="sourceId" type="string">411650</Field><Field name="corporatePublicationTitle" type="string">Products in development - Theragyn (pemtumomab) and ovarian cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-06-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Antisoma Inc</Field></Result><Result pos="102"><Field name="sourceId" type="string">414664</Field><Field name="corporatePublicationTitle" type="string">Corixa Corp product pipeline: cancer: Her2/neu for breast and ovarian cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-06T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Corixa Corp</Field></Result><Result pos="103"><Field name="sourceId" type="string">428985</Field><Field name="corporatePublicationTitle" type="string">Programs; Cancer, Angiogenesis, Inflammation, CNS, Metabolism</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Exelixis Inc</Field></Result><Result pos="104"><Field name="sourceId" type="string">415876</Field><Field name="corporatePublicationTitle" type="string">Clinical trials: allogenic whole cell vaccines: colorectal cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Onyvax Ltd</Field></Result><Result pos="105"><Field name="sourceId" type="string">416724</Field><Field name="corporatePublicationTitle" type="string">R&amp;amp;D: 6 programs/new vaccines/AIDS/immunotherapy/cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Aventis Pasteur SA</Field></Result><Result pos="106"><Field name="sourceId" type="string">416888</Field><Field name="corporatePublicationTitle" type="string">Cancer Therapeutics- Variagenic Targeting</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-26T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Variagenics Inc</Field></Result><Result pos="107"><Field name="sourceId" type="string">417249</Field><Field name="corporatePublicationTitle" type="string">Product pipeline: therapeutic vaccines for cancer - other cancer vaccines</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-07-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Therion Biologics Corp</Field></Result><Result pos="108"><Field name="sourceId" type="string">420394</Field><Field name="corporatePublicationTitle" type="string">Phase II trial of ISIS-2503 in patients with non-small cell lung cancer (NSCLC)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-08-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ISIS Pharmaceuticals Inc</Field></Result><Result pos="109"><Field name="sourceId" type="string">420391</Field><Field name="corporatePublicationTitle" type="string">Phase II trials of ISIS-2503 in patients with advanced pancreatic cancer</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-08-28T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ISIS Pharmaceuticals</Field></Result><Result pos="110"><Field name="sourceId" type="string">422212</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: p16/p53 gene therapy, gene therapy (pancreatic cancer), gene therapy (obesity), AdCMV.CD</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-09-11T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Merck Inc</Field></Result><Result pos="111"><Field name="sourceId" type="string">422853</Field><Field name="corporatePublicationTitle" type="string">Antibody therapies: the use of tumor-targeting monoclonal antibodies in molecular imaging and radioimmunotherapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-09-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ludwig Institute for Cancer Research</Field></Result><Result pos="112"><Field name="sourceId" type="string">427636</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: cancer therapy, ARIUS</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-11-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ARIUS Research Inc</Field></Result><Result pos="113"><Field name="sourceId" type="string">430151</Field><Field name="corporatePublicationTitle" type="string">Product pipeline: cancer and angiogenesis</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-11-22T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Exelixis Inc</Field></Result><Result pos="114"><Field name="sourceId" type="string">430471</Field><Field name="corporatePublicationTitle" type="string">Breast cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-11-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SignalGene Inc</Field></Result><Result pos="115"><Field name="sourceId" type="string">1363104</Field><Field name="corporatePublicationTitle" type="string">CAMPTOSAR + 5-FU/LV FOR FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: A POST-MARKETING REEVALUATION OF SAFETY</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-11-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Food and Drug Administration</Field></Result><Result pos="116"><Field name="sourceId" type="string">432716</Field><Field name="corporatePublicationTitle" type="string">InformedInvestors.com Virtual Cancer Stocks Forum</Field><Field name="corporatePublicationType" type="string">Company Presentation</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-12-04T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Genentech Inc</Field></Result><Result pos="117"><Field name="sourceId" type="string">433988</Field><Field name="corporatePublicationTitle" type="string">Annual Report 2000/2001: CRC Experimental Cancer Chemotherapy Research Group, School of Pharmaceutical Sciences, University of Nottingham</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-12-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">University of Nottingham</Field></Result><Result pos="118"><Field name="sourceId" type="string">490599</Field><Field name="corporatePublicationTitle" type="string">NY-ESO-1 in the clinic</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ludwig Institute for Cancer Research</Field></Result><Result pos="119"><Field name="sourceId" type="string">490400</Field><Field name="corporatePublicationTitle" type="string">New York Research</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2001-12-31T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Ludwig Institute for Cancer Research</Field></Result><Result pos="120"><Field name="sourceId" type="string">435141</Field><Field name="corporatePublicationTitle" type="string">Aventis Pasteur's cancer vaccine program</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-01-08T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Aventis Pasteur SA</Field></Result><Result pos="121"><Field name="sourceId" type="string">435657</Field><Field name="corporatePublicationTitle" type="string">Company profile</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-01-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Australian Cancer Technology Ltd</Field></Result><Result pos="122"><Field name="sourceId" type="string">435655</Field><Field name="corporatePublicationTitle" type="string">Developing healthier futures</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-01-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Australian Cancer Technology Ltd</Field></Result><Result pos="123"><Field name="sourceId" type="string">440139</Field><Field name="corporatePublicationTitle" type="string">Therapy development: New therapies</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-02-18T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research UK</Field></Result><Result pos="124"><Field name="sourceId" type="string">441377</Field><Field name="corporatePublicationTitle" type="string">Cancer Research Campaign Technology Limited: Key Patrners and Start-ups</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Campaign Technology Ltd</Field></Result><Result pos="125"><Field name="sourceId" type="string">441079</Field><Field name="corporatePublicationTitle" type="string">Cancer Research Ventures: About us</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-02-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Cancer Research Ventures Ltd</Field></Result><Result pos="126"><Field name="sourceId" type="string">490851</Field><Field name="corporatePublicationTitle" type="string">Fenretinide in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-01T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Institutes of Health</Field></Result><Result pos="127"><Field name="sourceId" type="string">441835</Field><Field name="corporatePublicationTitle" type="string">Antineoplastons</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">National Cancer Institute</Field></Result><Result pos="128"><Field name="sourceId" type="string">442488</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: Therapeutics (cancer, hypercholesterolemia, HIV), Samaritan</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Samaritan Pharmaceuticals Inc</Field></Result><Result pos="129"><Field name="sourceId" type="string">442162</Field><Field name="corporatePublicationTitle" type="string">Products: Cancer Immunotherapies</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-05T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Remedyne</Field></Result><Result pos="130"><Field name="sourceId" type="string">443404</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: oltipraz</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-12T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Fox Chase Cancer Center</Field></Result><Result pos="131"><Field name="sourceId" type="string">443512</Field><Field name="corporatePublicationTitle" type="string">Cancer products</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-14T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Progenics Pharmaceuticals Inc</Field></Result><Result pos="132"><Field name="sourceId" type="string">445419</Field><Field name="corporatePublicationTitle" type="string">Inhaled cancer therapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-20T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Battelle Pulmonary Therapeutics</Field></Result><Result pos="133"><Field name="sourceId" type="string">444671</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: cancer vaccine</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-25T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">ApoImmune Inc</Field></Result><Result pos="134"><Field name="sourceId" type="string">460461</Field><Field name="corporatePublicationTitle" type="string">Information for shareholders on the progress of the Canadian cancer pain trial</Field><Field name="corporatePublicationType" type="string">Company Publication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-03-27T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">International Wex Technologies Inc</Field></Result><Result pos="135"><Field name="sourceId" type="string">453175</Field><Field name="corporatePublicationTitle" type="string">Pipeline: therapeutic areas: cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-04-13T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Celltech Group plc</Field></Result><Result pos="136"><Field name="sourceId" type="string">447916</Field><Field name="corporatePublicationTitle" type="string">Breast cancer vaccine</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-04-16T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Vaccinex Inc</Field></Result><Result pos="137"><Field name="sourceId" type="string">475716</Field><Field name="corporatePublicationTitle" type="string">MinoVac breast cancer vaccines</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">BioLife Science Forschungs- und Entwicklungsges mbH</Field></Result><Result pos="138"><Field name="sourceId" type="string">475701</Field><Field name="corporatePublicationTitle" type="string">Hervac breast cancer vaccines</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">BioLife Science Forschungs- und Entwicklungsges mbH</Field></Result><Result pos="139"><Field name="sourceId" type="string">475695</Field><Field name="corporatePublicationTitle" type="string">BioLife Science -Vaccines for prevention and treatment of cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-10T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">BioLife Science Forschungs- und Entwicklungsges mbH</Field></Result><Result pos="140"><Field name="sourceId" type="string">1326665</Field><Field name="corporatePublicationTitle" type="string">Meditech's contribution to cancer fight</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-17T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string"></Field></Result><Result pos="141"><Field name="sourceId" type="string">452637</Field><Field name="corporatePublicationTitle" type="string">R&amp;amp;D pipeline: Melan-A/MART-1, dendritic/cancer cell fusion technology, antigen-specific melanoma vaccine, ESO-1 cancer vaccine, aaATIII, p53 gene-based therapy</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-24T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Genzyme Molecular Oncology</Field></Result><Result pos="142"><Field name="sourceId" type="string">453087</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: retinoid prophylatic therapy, MD Anderson Cancer Center</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-05-30T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">MD Anderson Cancer Center</Field></Result><Result pos="143"><Field name="sourceId" type="string">453815</Field><Field name="corporatePublicationTitle" type="string">Intercell: pipeline validation; cancer vaccine (Phase I), HCV vaccine (phase II), Tuberculosis vaccine (DR)</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-07T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Intercell Biomedical Research &amp; Development GmbH</Field></Result><Result pos="144"><Field name="sourceId" type="string">455169</Field><Field name="corporatePublicationTitle" type="string">Treatments for colorectal cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Wellstat Therapeutics</Field></Result><Result pos="145"><Field name="sourceId" type="string">455168</Field><Field name="corporatePublicationTitle" type="string">Treatment for Gastric Cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Wellstat Therapeutics</Field></Result><Result pos="146"><Field name="sourceId" type="string">455166</Field><Field name="corporatePublicationTitle" type="string">Treatments for Pancreatic Cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-06-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Wellstat Therapeutics</Field></Result><Result pos="147"><Field name="sourceId" type="string">457075</Field><Field name="corporatePublicationTitle" type="string">Review of the use of SRL-172 in the treatment of cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-07-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SR Pharma plc</Field></Result><Result pos="148"><Field name="sourceId" type="string">456821</Field><Field name="corporatePublicationTitle" type="string">SRL-172 in cancer</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-07-02T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">SR Pharma plc</Field></Result><Result pos="149"><Field name="sourceId" type="string">458836</Field><Field name="corporatePublicationTitle" type="string">Celsion, new cancer drugs</Field><Field name="corporatePublicationType" type="string">Company World Wide Web site</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-07-23T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Celsion Corp</Field></Result><Result pos="150"><Field name="sourceId" type="string">461769</Field><Field name="corporatePublicationTitle" type="string">Drug development pipeline: DeImmunized Abs (colon cancer), Biovation/CRC</Field><Field name="corporatePublicationType" type="string">Company Communication</Field><Field name="corporatePublicationDatePublication" type="datetime">2002-08-19T00:00:00Z</Field><Field name="corporatePublicationCompanyOwnerName" type="string">Biovation Ltd</Field></Result></PagedResults><DatasetCounts></DatasetCounts><HitTerms><Terms><Term>cancer</Term></Terms></HitTerms></ns2:com.thomson.ls.soa.stack.soaservices.service.contract.soap.v4.search.SearchOutput>